ProQR Therapeutics N.V.
PRQR
$1.63
$0.095.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.92M | -8.91M | -2.90M | -8.31M | -5.90M |
| Total Depreciation and Amortization | 715.30K | 756.40K | 765.30K | 750.10K | 783.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -182.30K | 710.20K | 364.90K | 1.15M | -3.08M |
| Change in Net Operating Assets | -578.80K | 1.23M | -4.97M | -10.01M | 2.47M |
| Cash from Operations | -9.96M | -6.22M | -6.73M | -16.43M | -5.73M |
| Capital Expenditure | -141.80K | -314.40K | -287.40K | -794.60K | -648.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 14.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.83M | 18.69M | -- | -18.45M | 6.02M |
| Cash from Investing | -2.97M | 18.38M | -287.40K | -19.25M | 5.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -253.00K | -454.00K | -294.00K | -581.00K | -1.29M |
| Issuance of Common Stock | 71.68M | 1.00K | 12.00K | 162.00K | 199.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 76.14M | -498.00K | -303.50K | -454.90K | -1.18M |
| Foreign Exchange rate Adjustments | 760.00K | -190.20K | 66.70K | 77.10K | -229.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.97M | 11.47M | -7.26M | -36.05M | -1.75M |